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Abstract
Background: The tumor suppressor gene CDKN2A generates at least three different transcriptional variants, each of 
which is thought to encode a tumor suppressor. However, the inhibitory activities of these variants have not yet been 
compared in the same cells. Protein therapy is known to have several advantages over gene therapy. Thus, 
investigation of the exogenous protein molecule of the most effective suppressor may yield meaningful information 
regarding protein-based cancer therapy.
Methods: The inhibitory effects of p16INK4a, p14ARF and p12 were studied in the human lung cancer cell line A549 
which lacks the CDKN2A locus. The eukaryotic expression plasmids of the three transcriptional variants were 
constructed and stably transfected into the cells. RNA and protein expression by the plasmids was confirmed using RT-
PCR and fluorescence immunocytochemistry, respectively. Cell growth inhibition and cell-cycle redistribution after 
transfection were investigated based on growth curve and flow cytometry analyses. An exogenous His-tag fusion 
p16INK4a protein was obtained and purified by affinity chromatography. Cell growth inhibition and cell cycle arrest 
induced by the expression of p16INK4a protein were measured in A549 cells transduced with the exogenous protein.
Results: While all three variants suppressed cell growth, p16INK4a had the strongest effect. Marked G1-phase 
accumulation and S-phase inhibition were induced by p16INK4a and p14ARF but not by p12. Exogenous p16INK4a 
protein was successfully expressed and purified and transduction of the fusion protein into A549 cells inhibited cell 
growth by G1TS arrest.
Conclusions: Among the three transcript variants, p16INK4a has a greater inhibitory effect than p14ARF and p12; 
exogenous p16INK4a protein should be further investigated for use in cancer therapy as a protein agent.
Background
The cell cycle is a strictly ordered process regulated by
positive regulators, including cyclins and cyclin-depen-
dent kinase (CDKs), and by negative regulators, such as
cyclin-dependent kinase inhibitors (CKIs) [1]. There are
two tyepes of CKIs: the INK4 family, which includes
CDKN2A, and the CIP/KIP family, of which, p21, directly
inducible by p53, is an example. Cell cycle regulators are
frequently mutated in many types of cancers such that
cancer is now considered a cell cycle disease[2]. Accord-
ingly, cell cycle regulators have become an important
focus in carcinogenesis research and cancer therapy.
The tumor suppressor gene CDKN2A, located at 9p21,
generates at least three structurally and functionally
unrelated transcriptional variants: p16INK4a,  p14ARF
and p12 [3]. In terms of structure, p16INK4a and p14ARF
share the exon 2 and 3 but use unique first exons and uti-
lize different reading frames. p16INK4a utilizes exon 1α
and p14ARF utilizes exon 1β which is 20 kb upstream of
exon 1α. p12 is a splice variant of an alternative donor
splice site within intron 1 of p16INK4a which contains
exon1α and a novel intron-1-encoded C-terminus[4].
(Figure 1). The protein products of these transcripts
function via different pathways. p16INK4a specifically
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binds to the cyclin-dependent kinases CDK4/6, thereby
inhibiting the phosphorylation of the retinoblastoma pro-
tein (pRB) and causing cell-cycle arrest at the G1 phase
[5]. p14ARF interacts with MDM2, which targets p53 for
degradation, thereby inducing p53-dependent cell-cycle
arrest in both G1 and G2 phases [6,7]. p53 participates in
a wide range of activities including growth arrest, DNA
repair and apoptosis and nearly 50% of human tumors
have defects in p53 [8]. Less is known about p12; pRB-
independent growth suppression by p12 was reported in
pancreatic cells, but the tumor suppressive and cell-cycle
effects of this protein are as yet unclear [4].
The CDKN2A locus is frequently inactivated in a wide
variety of tumors[9-12]. Kamb examined 290 tumor cell
lines and detected CDKN2A deletion in 133 of them [13].
Park examined 31 non-small cell lung cancer (NSCLC)
cell lines and found that the inactivation rate of
p16INK4a  and p14ARF was 84% and 55% respectively.
Significantly, p16INK4a was inactivated in all cell lines in
which p14ARF was inactivated[14]. Conversely, restora-
tion of the transcripts in tumors with endogenous expres-
sion deficiency has been shown to reverse the malignant
p h e n o t y p e s  o f  m a n y  t u m o r s .  I n  l u n g  c a n c e r  c e l l s ,  f o r
examples, Zhang X et al restored the expression of
p16INK4a in A549 cells and showed that p16INK4a could
suppress cell growth and block G1-S cell cycle transition
both in vitro and in vivo[15]. Elevated p16INK4a protein
expression also enhanced the sensitivity to cisplatin treat-
ment of NSCLC cells[16]. Xie Qi-chao et al co-trans-
fected  p16INK4a and  p14ARF  into the A549 cells and
found that cell growth arrest and apoptosis were induced
[17]. As for p12, little is known about its status and
tumor-suppressive effects. Keith et al transfected a p12
eukaryotic expression vector into C-33A and PANC-1
cells and found that the expression of the protein sup-
pressed cell growth by 40% and 60%, respectively, and
found no relationship with RB state. While all three tran-
scripts are potential tumor suppressors in different
genetic backgrounds, they may have different effects and
mechanisms. So far, the activity of the transcriptional
variants under the same condition has not been studied,
nor is it known which variant has the strongest suppres-
sion effect.
Inactivation of the CDKN2A locus has been shown to
efficiently impair expression of the three transcripts
simultaneously [18]. Thus, in tumors deficient in all three
transcripts, it is of interest to compare the effects of each
one against the same tumor background, considering the
potential significance of the findings with respect to can-
cer therapy. Accordingly, the aim of the present study was
to individually restore expression of the three transcripts
in a lung-cancer cell line with endogenous expression
deficiency and then to compare the inhibitory effects of
each one. Distinguishing the different effects of the
CDKN2A  variants will identify whether they differ in
their growth-inhibiting effects. This approach will, in
addition, reveal the function of p12 in lung cancer cells
Along with gene therapy, the use of protein therapeutic
agents is rapidly developing[19,20]. More encouragingly,
protein therapy has been shown to overcome the draw-
backs of vector-associated toxicity and immune
responses associated with gene therapy and to avoid its
delayed therapeutic impacts due to the need for tran-
scription and translation of the encoded protective pro-
tein[21]. It is therefore meaningful to identify the most
effective and useful suppressor for future applications as
a protein therapeutic agent.
Here, the different growth inhibition effects of
p16INK4a, p14ARF and p12 were investigated in a study
that included the exogenous expression, purification and
function of the p16INK4a protein. Our results demon-
strated the different effects of the three transcripts on cell
Figure 1 The three transcriptional variants of CDKN2A. The CDKN2A gene located at 9p21 generates three transcriptional variants at transcription: 
p16INK4a, p14ARF and p12. p16INK4a utilizes exon1α, and p14ARF utilizes exon 1β which is about 20 kb upstream of exon 1α. p16INK4a and p14ARF 
share common exon 2 and exon 3 but use different reading frames. p12 uses an alternative splice donor site within intron1 of p16INK4a.Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:74
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growth and their activity at different phases of the cell
cycle. Among the three variants, p16INK4a was shown to
more effectively suppress the growth of A549 lung cancer
cells. Our research on the p16INK4a protein could facili-
tate or improve the basic understanding of future cancer
biotherapy with the p16INK4a protein.
Methods
Cell culture
The human lung cancer cell line A549, deficient in the
CDKN2A locus and wild-type in RB and p53 [22], was
obtained from the Cell Resource Center of the Shanghai
Academy of Sciences The cells were cultured in F12-K
medium (Sigma-Aldrich, St.Louis, MO) supplemented
with 10% fetal bovine serum (FBS) (GIBCO BRL) in a
humidified 5% CO2 air incubator at 37°C.
Plasmids construction and stable transfection
Full-length fragments of complementary DNA (cDNA)
corresponding to p16INK4a,  p14ARF  and  p12  were
obtained by reverse transcription polymerase chain reac-
tion (RT-PCR) from AGZY and H446 cells and normal
pancreas tissue, respectively, which were positive for the
respective transcript. The PCR products were cloned into
pGEM-T vector (Promega, Medison, WI). The PCR
products were cloned into the vector pGEM-T (Promega,
Medison, WI) and the transcripts PCR-amplified using
primers containing the same restriction-enzyme sites as
the clone vector plasmids. Primers for p16INK4a were 5'-
CCCAAGCTTGCATGGAGCCGGCGGCG-3' and 5'-
CGGGATCCCTTTCAATCGGGGATGT-3'. Primers for
p14ARF  were 5'-CCCAAGCTTAGATGGGCAG-
GGGGCGG-3' and 5'-CGGGATCCCTCCTCAGCCAG-
GTCCA-3'. Primers for p12  were 5'-
CCCAAGCTTGCATGGAGCCGGCGGCG-3' and 5'-
CGGGATCCCCTCATTCCTCTTCCTT-3'. The PCR
products and pcDNA3 vector were double-digested with
HindIII and BamHI (TaKaRa, Japan). Eukaryotic expres-
sion plasmids were constructed, verified by DNA
sequencing, and then used to transfect A549 cells using
the Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA). Transfection of the empty pcDNA3 vector
served as the control. The stably transfected cells were
screened by adding 600 mg G418/L for 14 days. Positive
cell clones were selected and gene expression subse-
quently confirmed by RT-PCR (with the same primers as
described above) and fluorescence immunocytochemis-
try analyses.
Protein expression, purification and transduction
p16INK4a cDNA was PCR-amplified from clone vector
plasmids with primers 5'-TACCGAGCTCGGATCCCG-
GAGAG-3' and 5'-GTCTCGAGCATGCATCTAGAG-3'.
The p16INK4a cDNA and the pQE-31 vector (QIAGEN)
were double-digested with BamHI  and  SphI  (TaKaRa,
Japan). The PQE31-p16INK4a plasmid was constructed
and transformed into BL21(DE3) competent cells. The
positive clone (confirmed by DNA sequencing) was
grown at 37°C in LB medium supplemented with 100 mg
ampicillin/L until the absorbance at 600 nm reached 0.6.
Protein expression was induced overnight at 25°C with
isopropy-β-D-thiogalactoside (IPTG) at a final concen-
tration of 0.1 mmol/L. The Cells were harvested, resus-
pended in 20 mL lysis buffer (0.5 M/L NaH2PO4, 0.5 M/L
Na2HPO4, 29.3 g NaCl/L, pH 7.4), lysed by ultrasonica-
tion and centrifuged at 12,000 ×g for 30 minutes at 4°C.
The supernatant was loaded onto a Ni2+-Agarose column.
Nonspecific binding was removed with washing buffer
(50 mmol Na2HPO4/L, 0.3 mol NaCl/L, 10--50 mmol
imidazole/L, pH 8.0). The His-tag fusion p16INK4a pro-
tein was eluted with elution buffer (50 mmol Na2HPO4/L,
0.3 mol NaCl/L, 20--200 mmol imidazole/L, pH 8.0).
Purified protein was analyzed by 12% SDS-PAGE and
Western-blotting. Protein was transduction into A549
cells using Lipofectamine 2000 reagent. After 6 h of incu-
bation, the culture mixture was replaced with fresh
medium. The transduction efficiency was verified by flu-
orescence immunocytochemistry.
Western blot analysis
Fifty μg protein was separated by 12% SDS-PAGE and
transferred to polyvinylidene difluoride membranes
(Immobilon-P; Millipore, Bedford, MA). The membranes
were blocked, washed, and then incubated with primary
p16INK4a antibody (monoclonal mouse anti-human,
Santa Cruz, 1:200) for 1 h, followed by a second wash and
incubation with secondary antibody (monoclonal goat
anti-mouse, 1:2000) for 1 h. Bands were visualized using
an enhanced chemiluminescence (ECL) detection kit
(Amersham, UK).
Fluorescence immunocytochemistry
Plasmids- or protein- transduced cells were seeded on
cover slips in 6-well plates at a density of 5 × 104 cells/mL.
After 24 h of incubation, cells adhered to cover slips were
washed in cold phosphate-buffered saline (PBS), fixed in
4% paraformaldehyde for 15 min, and permeabilized in
PBS with 0.1% Triton X-100 for 15--20 min. The fixed
cells were then incubated in 1:200 diluted primary anti-
bodies (anti-human p16INK4a/p12 was from Santa Cruz
(SC-468), and anti-human p14ARF from Fujian Maixin
Corp., China) at 37°C for 2 h, washed, and incubated for 2
h with 1:50 diluted FITC-conjugated secondary antibod-
ies (Beijing Zhongshan Golden Bridge Biotechnology
Corp., China). The pcDNA-vector-transfected cells were
stained with anti-p16INK4a/p12 and anti-p14ARF anti-
bodies. The nuclei of A549 cells transduced withZhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:74
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p16INK4a protein were counterstained using Hoechst
stain.
Cell growth suppression assays
Transduced cells or control cells were seeded onto 24-
well plates at an initial density of 1 × 104 cells/mL and
then trypsinized, harvested, and counted at 24-h intervals
(plasmid transfection groups) or 12-h intervals (protein
transduction groups). The cell number at each time point
was determined in three separate wells and experiments
were independently repeated at least three times.
Cell cycle analysis
The redistribution of cells in the cell cycle was analyzed
by flow cytometry analysis. After 48 h of cultivation,
transduced cells and the control groups were harvested
by trypsinization, washed with PBS and fixed in 75% eth-
anol at 4°C for 24 h. The cycle TEST? PLUS DNA Reagent
Kit (BD Biosciences, San Jose, CA) was used for cell sam-
ple preparation and DNA staining according to the man-
ufacturer's guidelines. Cell cycle distribution was
analyzed by flow cytometry analysis (Bio-Rad, Richmond,
CA). All experiments were repeated at least three times.
Statistical analysis
All values are expressed as means ± SD. Student's t-test
was used to assess statistical differences. A p value < 0.05
was considered significant.
Results
Construction and identification of A549 cell clones stably 
expressing exogenous p16INK4a, p14ARF and p12
Full-length cDNAs were cloned into pcDNA3 vectors
designated as pcDNA3-p16INK4a, pcDNA3-p14ARF,
and pcDNA3-p12, verified by DNA sequencing (data not
shown), and stably transfected into A549 cells. Positive
cell clones were identified by G418 screening for 14 days
and the expression of exogenous p16INK4a, p14ARF, or
p12  examined by RT-PCR and immunocytochemical
assays.
RT-PCR of the transfected cells confirmed the presence
of products of the expected sizes (493, 543, and 372 bp)
(Figure 2a). Immunocytochemical assay results were in
agreement with the RT-PCR results and showed signifi-
cant green fluorescence in cells transfected with each of
the three transcripts, thus demonstrating protein expres-
sion. The empty-plasmid group stained with anti-
p16INK4a/p12 and anti-p14ARF antibodies did not show
fluorescence, excluding the background signals (Figure
2b).
Differential effects of p16INK4a, p14ARF and p12 on growth 
control of A549 cells
Growth arrest effects of the three transcripts were
assessed by measuring the growth of the stably trans-
fected clones over a period of 1 week at 24-h intervals.
Figure 3a shows a reduction in the growth rate of cells
transfected with p16INK4a, p14ARF, and p12 compared
with the control group after day 3. During the following 3
days, the growth suppression effects became even more
pronounced. As seen in Figure 3b, on the final day of cell
counting, proliferation of the cells carrying any one of the
three transcriptional variants was significantly inhibited
compared to cells carrying the empty expression vector.
Moreover,  p16INK4a  had a greater suppressive effect
than p14ARF and p12.
To determine the mechanisms responsible for cell
growth suppression, the stable transfected cells were ana-
lyzed by flow cytometry, which allowed comparison of
the cell cycle distribution of the cells after 48 h of subcul-
ture (Figure 3c). Both p16INK4a and  p14ARF  induced
marked increases in the number of cells in G0/G1 phase
Figure 2 Identification of stable A549 cell clones for RNA and pro-
tein expression.a. RT-PCR detection of RNA expression of p16INK4a 
(lane 1), p14ARF (lane 2) and p12 (lane 3). The products were analyzed 
by 1% agarose gel electrophoresis. Lane M was loaded with DL 2000 
DNA marker, with sizes shown on the left. b. Immunocytochemical as-
says detected expression of p16INK4a, p14ARF and p12 proteins in the 
cell clones. No specific signal was detected in the negative control 
(pcDNA3 vector-transfected cells).Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:74
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and a decrease in the number of those in S phase,
whereas pcDNA3-p12-transfected cells shows no signifi-
cant cell cycle changes.
Since p16INK4a had the greatest growth suppressive
effects, the protein was investigated in further studies,
described below.
Expression of exogenously induced p16INK4a transduced 
into A549 cells
To produce exogenous p16INK4a protein, plasmid
pQE31-p16INK4a-BL21 was generated and confirmed by
DNA sequencing. Figure 4a shows the almost complete
absence of bacterial protein expression before IPTG
induction, whereas after induction, a His-tag fusion pro-
tein of approximately 20 kDa was produced that was
present in abundance in the supernatant of an extract
prepared from the bacterial cells. For protein purification,
the supernatant was loaded onto a Ni2+-affinity chroma-
tography columns and cell proteins eluted with different
concentrations of imidazole. The target protein was
found to be enriched in the 100 mM imidazole eluent. All
samples were analyzed by 12% SDS-PAGE. The
p16INK4a fusion protein was further verified by Western
blotting using a specific anti-p16INK4a antibody (Figure
4b).
Purified p16INK4a fusion protein was transduced into
A549 cells and transduction efficiency was examined by
fluorescence immunocytochemistry. As shown in Figure
4c, all A549 cell nuclei were positive for Hoechst fluores-
cence and about 50% were positive for FITC, indicating
that these cells had been successfully transduced with
p16INK4a.
Growth suppression of A549 cells following p16INK4a 
induction
To evaluate the effect of p16INK4a on cell growth, the
growth curves of A549 cells transduced with the protein
were compared with those of control cells (A549 cells
Figure 3 Cell growth inhibition and cell cycle redistribution analyses of stably transfected A549 cells. a. Cell growth curve analysis in one rep-
resentative experiment. Data shown are the mean ± standard deviation of triplicate wells. b. Comparison of cell growth inhibition effects of p16INK4a, 
p14ARF and p12 on the final day of cell counting, based on three independent experiments. It was shown that all three transcripts significantly sup-
pressed cell growth compared with the empty vector, but p16INK4a had the strongest effect. Error bars represent the standard deviation.* p < 0.05, ** 
p < 0.01. c. The percentage of stable clone cells at each stage of the cell cycle 48 h after subculture. p16INK4a and p14ARF induced clear G0/G1-phase 
accumulation and a decrease in the number of cells in S phase. p12 did not have a significant effect on the A549 cell cycle. Data shown are the mean 
± standard deviation of three independent experiments. * p < 0.05.
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incubated with Lipofectamine 2000). Cells transduced
with p16INK4a the day before the start of the experiment
were counted at 12-h intervals. Figure 5a shows that, 36 h
after cell subculture, p16INK4a began to induce growth
retardation. At 72 h, p16INK4a had significantly sup-
pressed proliferation compared with the control (Figure
5a, b). Furthermore, cell cycle changes, as analyzed by
flow cytometry (Figure 5c), showed that the presence of
exogenous p16INK4a resulted in a marked retardation of
the G1TS transition of A549 cells 48 h after transduction.
Discussion
As a tumor suppressor, CDKN2A is an important gene
because its inactivation abrogates two fundamental path-
ways, that of pRB and p53, both of which are involved in
carcinogenesis and tumor progression. So far, the distinct
tumor suppressive effects of p16INK4a and p14ARF have
been established, but those of p12 have not. Furthermore,
to the best of our knowledge, the effects of the three tran-
scripts have not been compared.
The human A549 cell line is a good model to investigate
the suppression effects of each of the three transcript
variants. The advantages of this cell line are as follows:
First, the CDKN2A locus is homozygously deleted in this
cell line, such that there is no interference from the
endogenous proteins. This is an important consideration
since the effects of p16INK4a were shown in a previous
study to be associated with endogenous p16INK4a status
[23,24]. Previous research in our laboratory also demon-
strated that introduction of p16INK4a neither suppresses
growth nor decreases colony formation rates by Anip973
and AGZY83-a cells expressing endogenous wild-type
p16INK4a [25]. Second, the A549 cell line is wild-type in
RB and p53. Therefore, p16INK4a and p14ARF plasmids
can be expected to successfully act on the pRB and p53
pathways. As to the methods used in this study, the use of
stable transfectants confers several advantages as it elimi-
nates a source of variability in transfection efficiency,
which facilitated parallel comparison experiments. Fur-
thermore, the characteristics of cells stably transfected
with  p16INK4a  have been shown to differ from those
transiently transfected with the vector; transient
p16INK4a transfection induces apoptosis whereas stable
transfection markedly suppresses cell growth and cloning
efficiency [26].
Research on p12  has been hindered as the gene is
expressed in normal pancreas tissue, which is difficult to
obtain in a well-preserved state. We successfully con-
structed a eukaryotic expression vector carrying p12 and
were thus able to show that the gene acts as a prolifera-
tion inhibitor in A549 cells. Thus, our research provides
evidence that p12 has tumor suppressive effects not only
in pancreatic and cervical cancer cell lines, as previously
reported, but also in a lung cancer cell line. The effects of
p12 on other cell types will be investigated in future stud-
ies. Interestingly, however, p12 had no clear effect on the
cell cycle of A549 cells. This finding is in accordance with
the report that p12 cannot bind cyclin-dependent kinase
CDK4 and acts in a pRb-independent manner [4]. The
exact mechanism by which p12 suppresses cell growth
remains to be determined. The p12 expression plasmid
constructed as part of this study will facilitate investiga-
tions into the mechanistic pathway of this transcript.
The different growth suppressive effects of the three
transcripts and the possible mechanisms responsible for
these differences were compared in growth arrest experi-
ments and by cell cycle analysis. All three transcripts
showed significant growth arrest effects compared with
the control. Specifically, p16INK4a and p14ARF caused
m a r k e d  G 1 - p h a s e  a c c u m u l a t i o n  a n d  a  d e c r e a s e  i n  t h e
n um be r o f  c e l ls  i n S phase ,  bot h o f  whi c h e x p la in t he
observed growth inhibition. Notably, p16INK4a had the
greatest growth suppressive effect among the three vari-
ants while the effects of p14ARF and p12 were similar.
Figure 4 Purification, verification, and transduction of exoge-
nous p16INK4a fusion protein. a. Successful expression and purifica-
tion of the p16INK4a fusion protein was confirmed by 12% SDS-PAGE 
analysis. The bacterial sample before IPTG induction showed almost no 
protein expression (lane 1). After IPTG induction and centrifugation, 
p16INK4a fusion protein was abundant in the clear supernatant (lane 
3) (indicated by the arrow) and absent from the bacterial precipitate 
(lane 2). The supernatant was loaded onto a Ni2+-affinity chromatogra-
phy column, which binds the His-p16INK4a fusion protein. Nonspecif-
ically bound proteins were removed with washing buffer; the flow-
through liquid can be seen in lane 4. Elution buffer with different con-
centrations of imidazole was used to elute the p16INK4a fusion pro-
tein: 20 mM (lane 5), 50 mM nt (lane 6), 100 mM (lane 7) and 200 mM 
(lane 8) were. The fractions were assessed by SDS-PAGE and the sam-
ple corresponding to the 100 mM imidazole eluent (lane 7) was found 
to contain p16INK4a fusion protein of high purity (arrow). b. The puri-
fied protein was verified by Western-blot analysis using the specific 
p16INK4a antibody. c. Immunocytochemical assay to assess transduc-
tion efficiency. All nuclei of A549 cells stained with Hoechst fluorescent 
and the exogenous p16INK4a protein was detected in about 50% of 
cells, as shown by the FITC signal. As shown in the figure, the transduc-
tion efficiency was about 50%.Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:74
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This result provides meaningful information in the con-
text of tumor suppressor selection, especially in cells in
which CDKN2A is inactivated.
As an important complement to gene therapy, protein
therapy has its own advantages and its future applications
are promising. The administration of protein therapeutic
agents has proved to be feasible and effective both in vitro
and in vivo [27-29]. In the present study, p16INK4a was
exogenously expressed and purified and its tumor sup-
pression effects verified in the A549 cell line. This protein
is of interest for the following reasons: First, p16INK4a
more effectively inhibited cell growth than either p14ARF
or p12. Second, p16INK4a has a low molecular weight,
which makes it suitable for protein therapy applications.
Third, in contrast to other proteins such as p53, which is
involved in a broad range of biological activities,
p16INK4a specifically binds CDK4/6. In the present
study, the protein was successfully purified and demon-
strated to inhibit the proliferation of A549 cells in vitro.
The structure and function of p16INK4a will be studied
in further investigations, which are likely to provide
insight into the use of this protein as a therapeutic agent.
Conclusions
Our research is the first to show that, although all three
transcripts of the CDKN2A gene can suppress the growth
of lung cancer cells with an inactivated CDKN2A locus,
they have different effects, with the growth inhibitory
effect of p16INK4a being the strongest. Inhibitory effects
on cell growth by p16INK4a and p14ARF, but not by p12,
involve cell cycle redistribution. Thus, p16INK4a may be
a candidate agent for cancer biotherapy.
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Figure 5 Cell growth inhibition and cell cycle redistribution effects of p16INK4a in A549 cells. Cell growth curve in a representative experiment 
(a) and analysis of the differential inhibition effects of the three variants in three independent experiments carried out after 72 h of subculture (b). 
Significant growth retardance was exerted by p16INK4a compared with the control. The protein was transduced the day before cell counting. Data 
shown are the mean ± standard deviation of triplicate wells or experiments. **p < 0.01. c. p16INK4a protein caused evident accumulation of A549 cells 
in G1 phase and a decrease of those in S phase at 48 h after subculture. Data shown are the mean ± standard deviation of three independent exper-
iments. *p < 0.05.
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